Jonathan Brugger, MD
Ophthalmology · Sarasota, FLNPI 1013172105
Payments from drug & device makers
Across 535 payments — averaging $57.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Notal Vision, Inc.$17K
- Genentech USA, Inc.$7K
- Regeneron$2K
- Roche TCRC, Inc.$1K
- Astellas Pharma US Inc$1K
- Apellis Pharmaceuticals, Inc.$930
- plus $1K from 14 others
Across 1 payment — averaging $334.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$334
What the payments were for
- Consulting fees$6,10541%
- Speaking & faculty fees$5774%
- Travel & lodging$3,25322%
- Food & beverage$4,88033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Notal Vision, Inc. | 439 | $16,506 |
| Genentech USA, Inc. | 18 | $7,429 |
| Regeneron | 4 | $1,733 |
| Roche TCRC, Inc. | 3 | $1,500 |
| Astellas Pharma US Inc | 30 | $1,304 |
| Apellis Pharmaceuticals, Inc. | 9 | $930 |
| Alcon | 4 | $444 |
| Coherus Oncology, Inc. | 1 | $150 |
| AbbVie | 8 | $143 |
| Eyepoint US, Inc. | 2 | $138 |
| NEW World Medical,inc. | 1 | $110 |
| Bausch & Lomb Americas Inc. | 4 | $90 |
| Dutch Ophthalmic, USA | 1 | $80 |
| Novartis | 4 | $78 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Harrow Eye, LLC | 2 | $64 |
| Genentech, Inc. | 1 | $62 |
| Lensar, Inc. | 1 | $34 |
| Carl Zeiss Meditec USA, Inc. | 1 | $17 |
| Alimera Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUSVIMO$3,898
- VABYSMO$3,124
- Non-Covered Product$1,500
- Syfovre$712
- Izervay$560
- Unity$295
- Cimerli$150
- YUTIQ$125
- Constellation$124
- Kahook Dual Blade$110
- Clearpath$110
- Ahmed Glaucoma Valve$110
- Streamline$110
- Via360$110
- Foresee Home$106
How this compares
$30,895 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 113 | $4,092 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 228 | $2,483 |
| Brimonidine Tartrate | 15 | $1,088 |
| Ketorolac Tromethamine | 19 | $753 |
| Latanoprost | 66 | $618 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 25 | $592 |
| MoxifloxacinMoxifloxacin Hcl | 20 | $420 |
| Dorzolamide Hcl | 13 | $291 |
| Timolol Maleate | 14 | $54 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Sarasota
- Daniel KiernanSarasota$1.8M
- Jody AbramsSarasota$515K
- Robert SnyderSarasota$387K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.